Biomrieux Sa Stock Performance
| BMXMF Stock | USD 127.51 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioMérieux's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioMérieux is expected to be smaller as well. At this point, bioMrieux SA has a negative expected return of -0.0813%. Please make sure to confirm BioMérieux's variance, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if bioMrieux SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days bioMrieux SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable primary indicators, BioMérieux is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 371.3 M | |
| Total Cashflows From Investing Activities | -307.3 M |
BioMérieux |
BioMérieux Relative Risk vs. Return Landscape
If you would invest 13,501 in bioMrieux SA on September 30, 2025 and sell it today you would lose (750.00) from holding bioMrieux SA or give up 5.56% of portfolio value over 90 days. bioMrieux SA is currently producing negative expected returns and takes up 1.3722% volatility of returns over 90 trading days. Put another way, 12% of traded pink sheets are less volatile than BioMérieux, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioMérieux Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioMérieux's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as bioMrieux SA, and traders can use it to determine the average amount a BioMérieux's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0593
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMXMF |
Based on monthly moving average BioMérieux is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioMérieux by adding BioMérieux to a well-diversified portfolio.
BioMérieux Fundamentals Growth
BioMérieux Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioMérieux, and BioMérieux fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioMérieux Pink Sheet performance.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.99 B | |||
| Shares Outstanding | 118.37 M | |||
| Price To Earning | 23.91 X | |||
| Price To Book | 3.18 X | |||
| Price To Sales | 3.63 X | |||
| Revenue | 3.38 B | |||
| EBITDA | 1.01 B | |||
| Cash And Equivalents | 524.2 M | |||
| Cash Per Share | 4.43 X | |||
| Total Debt | 362.8 M | |||
| Debt To Equity | 0.17 % | |||
| Book Value Per Share | 29.31 X | |||
| Cash Flow From Operations | 811.1 M | |||
| Earnings Per Share | 4.99 X | |||
| Total Asset | 4.62 B | |||
| Retained Earnings | 86 M | |||
| Current Asset | 1.06 B | |||
| Current Liabilities | 644 M | |||
About BioMérieux Performance
By analyzing BioMérieux's fundamental ratios, stakeholders can gain valuable insights into BioMérieux's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioMérieux has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioMérieux has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
bioMrieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as B-D Mrieux. bioMrieux S.A. was founded in 1963 and is headquartered in Marcy lEtoile, France. bioMrieux S.A. is a subsidiary of Institut Mrieux SA. Biomerieux operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 12084 people.Things to note about bioMrieux SA performance evaluation
Checking the ongoing alerts about BioMérieux for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for bioMrieux SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| bioMrieux SA generated a negative expected return over the last 90 days | |
| About 64.0% of the company shares are held by company insiders |
- Analyzing BioMérieux's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioMérieux's stock is overvalued or undervalued compared to its peers.
- Examining BioMérieux's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioMérieux's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioMérieux's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioMérieux's pink sheet. These opinions can provide insight into BioMérieux's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioMérieux Pink Sheet analysis
When running BioMérieux's price analysis, check to measure BioMérieux's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMérieux is operating at the current time. Most of BioMérieux's value examination focuses on studying past and present price action to predict the probability of BioMérieux's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMérieux's price. Additionally, you may evaluate how the addition of BioMérieux to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |